Serum test identifies patients deriving benefit from CPIs 201 5 5. Patient characteristics by test classification Supplementary Table S15: Patient characteristics by test classification (development cohort). Resistant (n=41) Intermediate (n=43) Sensitive (n=32) P value n (%) n (%) n (%) Gender Male 25 (61) 22 (51) 19 (59) 0.649 Female 16 (39) 21 (49) 13 (41) Age Median (range) 68 (52-83) 63 (43-80) 64 (49-82) -- Histology Two primary tumors 1 (2) 1 (2) 0 (0) 0.474 Adenocarcinoma 25 (61) 27 (63) 25 (78) NSCLC-NEC 0 (0) 2 (5) 1 (3) NSCLC-NOS 2 (5) 4 (9) 2 (6) Squamous 13 (32) 9 (21) 4 (13) Performance Status (WHO) 0 8 (20) 13 (30) 15 (47) 0.112 1 22 (54) 24 (56) 14 (44) 2 8 (20) 3 (7) 1 (3) 3 2 (5) 1 (2) 0 (0) NA 1 (2) 2 (5) 2 (6) Smoking Status Current 10 (24) 6 (14) 7 (22) 0.431 Former 26 (63) 35 (81) 20 (63) Never 4 (10) 2 (5) 4 (13) NA 1 (2) 0 (0) 1 (3) Brain metastases at start of therapy No 31 (76) 32 (74) 24 (75) >0.999 Yes 10 (24) 11 (26) 8 (25) Previous radiotherapy No 13 (32) 15 (35) 15 (47) 0.389 Yes 28 (68) 28 (65) 17 (53) Previous thoracic radiotherapy No 30 (73) 24 (56) 25 (78) 0.087 Yes 11 (27) 19 (44) 7 (22) PD-L1 expression Positive (≥1%) 10 (24) 13 (30) 10 (31) 0.387 Negative (<1%) 16 (39) 19 (44) 8 (25) NA 15 (37) 11 (26) 14 (44)
RkJQdWJsaXNoZXIy MTk4NDMw